A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

To evaluate the safety, tolerability and pharmacokinetics of ABT-072 in healthy volunteers and its anti-viral activity in HCV infected subjects.

Phase 1

Abbott